UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission File Number. 001-40729

MYSEUM, INC.

(Exact name of registrant as specified in its charter)

Nevada		47-2502264
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

65 Church Street, Suite 230
New Brunswick, NJ		08901
(Address of principal executive offices)		(Zip Code)

(732) 374-3529
(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	MYSE	The Nasdaq Stock Market LLC
Series A Warrants, each warrant exercisable for one share of Common Stock at an exercise price of $4.98 per share	MYSEW	The Nasdaq Stock Market LLC

Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulations S-T (§232.405 of this chapter) during the preceding 12 months (or for shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 13, 2025, there were 4,264,329 shares of common stock, par value $0.0001 per share, outstanding.

MYSEUM, INC.

FORM 10-Q

September 30, 2025

INDEX

		Page
PART I. FINANCIAL INFORMATION		1

Item 1.	Financial Statements	1
	Consolidated Balance Sheets - As of September 30, 2025 (unaudited) and December 31, 2024	1
	Consolidated Statements of Operations and Comprehensive Loss - For the Three and Nine Months ended September 30, 2025 and 2024 (unaudited)	2
	Consolidated Statements of Changes in Stockholders’ Equity – For the Three and Nine Months ended September 30, 2025 and 2024 (unaudited)	3
	Consolidated Statements of Cash Flows - For the Nine Months ended September 30, 2025 and 2024 (unaudited)	5
	Notes to Unaudited Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	24
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	30
Item 4.	Controls and Procedures	30

PART II. OTHER INFORMATION		31

Item 1.	Legal Proceedings	31
Item 1A.	Risk Factors	31
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	31
Item 3.	Defaults Upon Senior Securities	31
Item 4.	Mine Safety Disclosures	31
Item 5.	Other Information	32
Item 6.	Exhibits	32
Signatures		33

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Any statements in this Quarterly Report on Form 10-Q about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as “believe,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “plan” and “would.” For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, industry ranking, plans and objectives of management, markets for our common stock and future management and organizational structure are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement.

Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed throughout our Annual Report on Form 10-K as filed with the SEC on March 31, 2025. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include, but are not limited to:

●

our business strategies;

●

the timing of regulatory submissions;

●

our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain;

●

risks related to market acceptance of products;

●

intellectual property risks;

●

risks associated to our reliance on third party organizations;

●

our competitive position;

●

our industry environment;

●

our anticipated financial and operating results, including anticipated sources of revenues;

●

assumptions regarding the size of the available market, benefits of our products, product pricing and timing of product launches;

●

management’s expectation with respect to future acquisitions;

●

statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and

●

our cash needs and financing plans.

The foregoing list sets forth some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed as exhibits our Annual Report on Form 10-K, completely and with the understanding that our actual future results may be materially different from what we expect. You should assume that the information appearing in this Quarterly Report on Form 10-Q is accurate as of the date hereof. Because the risk factors referred to in our Annual Report on Form 10-K, as filed with the SEC on March 31, 2025, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as required by law, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all the information presented in this Quarterly Report on Form 10-Q, and particularly our forward-looking statements, by these cautionary statements.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

MYSEUM, INC. AND SUBSIDIARIES AND CONSOLIDATED ENTITIES

CONSOLIDATED BALANCE SHEETS

	September 30,			December 31,
	2025			2024
	(Unaudited)
ASSETS

CURRENT ASSETS:
Cash and cash equivalents	$	457,626		$	1,196,699
Short-term investments, at fair value		4,346,310			2,952,512
Accounts receivable		224			207
Prepaid expenses		276,873			138,604

Total Current Assets		5,081,033			4,288,022

NON-CURRENT ASSETS:
Deferred offering costs		206,528			-
Property and equipment, net		21,635			33,436
Capitalized internal-use software, net		1,231,626			1,050,000
Operating lease right-of-usee asset, net		223,033			-

Total Non-current Assets		1,682,822			1,083,436

Total Assets	$	6,763,855		$	5,371,458

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
Notes payable	$	40,000		$	-
Accounts payable and accrued expenses		798,922			630,223
Operating lease liability, current portion		48,732			-
Contract liabilities		63			88

Total Current Liabilities		887,717			630,311

LONG-TERM LIABILITIES:
Operating lease liability, less current portion		181,565			-

Total Long-Term Liabilities		181,565			-

Total Liabilities		1,069,282			630,311

Commitments and Contingencies (Note 10)

STOCKHOLDERS' EQUITY:
Preferred stock ($0.0001 par value; 20,000,000 shares authorized)
Series A Preferred stock ($0.0001 Par Value; 1 Share designated; none issued and outstanding on September 30, 2025 and December 31, 2024)		-			-
Series B Preferred stock ($0.0001 Par Value; 2,000,000 Share designated; 2,000,000 issued and outstanding on September 30, 2025 and December 31, 2024)		200			200
Common stock ($0.0001 par value; 180,000,000 shares authorized; 4,331,274 and 3,076,274 shares issued and 4,264,329 and 3,009,329 shares outstanding on September 30, 2025 and December 31, 2024, respectively)		433			308
Common stock to be issued (139 shares on September 30, 2025 and December 31, 2024)		-			-
Additional paid-in capital		64,999,536			59,649,645
Treasury stock, at cost (66,945 shares on September 30, 2025 and December 31, 2024)		(397,969	)		(397,969	)
Accumulated deficit		(56,264,793	)		(52,373,248	)
Total Myseum, Inc. Stockholders' Equity		8,337,407			6,878,936
Noncontrolling interest		(2,642,834	)		(2,137,789	)

Total Stockholders' Equity		5,694,573			4,741,147

Total Liabilities and Stockholders' Equity	$	6,763,855		$	5,371,458

See accompanying notes to unaudited consolidated financial statements.

MYSEUM, INC. AND SUBSIDIARIES AND CONSOLIDATED ENTITIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2025			2024			2025			2024

NET REVENUES	$	328		$	62		$	489		$	344

OPERATING EXPENSES:
Compensation and related expenses		775,965			461,422			2,422,352			1,881,682
Marketing and advertising expenses		54,087			34,134			164,590			101,734
Professional and consulting expenses		221,275			222,220			1,087,655			726,119
Research and development expense		-			363,472			11,000			823,448
General and administrative expenses		229,602			156,998			662,767			636,067

Total operating expenses		1,280,929			1,238,246			4,348,364			4,169,050

LOSS FROM OPERATIONS		(1,280,601	)		(1,238,184	)		(4,347,875	)		(4,168,706	)

OTHER INCOME (EXPENSES):
Interest income, net		49,120			54,726			140,095			232,191
Gain on deconsolidation of variable interest entities		-			-			-			107
Foreign currency exchange loss		-			-			-			(12,965	)

Total other income, net		49,120			54,726			140,095			219,333

NET LOSS		(1,231,481	)		(1,183,458	)		(4,207,780	)		(3,949,373	)

Net loss of subsidiary attributable to noncontrolling interest		30,004			(88,343	)		316,235			556,513

NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$	(1,201,477	)	$	(1,271,801	)	$	(3,891,545	)	$	(3,392,860	)

COMPREHENSIVE LOSS:
Net loss	$	(1,231,481	)	$	(1,183,458	)	$	(4,207,780	)	$	(3,949,373	)

Other comprehensive gain:
Unrealized foreign currency translation gain		-			-			-			12,965

Comprehensive loss	$	(1,231,481	)	$	(1,183,458	)	$	(4,207,780	)	$	(3,936,408	)

NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS PER COMMON SHARE:
Basic and diluted	$	(0.28	)	$	(0.42	)	$	(0.93	)	$	(1.15	)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:
Basic and diluted		4,221,883			3,009,329			4,174,000			2,941,862

See accompanying notes to unaudited consolidated financial statements.

MYSEUM, INC. AND SUBSIDIARIES AND CONSOLIDATED ENTITIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

(Unaudited)

	Series B Preferred Stock				Common Stock				Common Stock to be Issued				Additional Paid-in			Treasury Stock					Accumulated Other Comprehensive		Accumulated			Noncontrolling			Total Stockholders’
	Shares		Amount		Shares		Amount		Shares		Amount		Capital			Shares		Amount			Gain (Loss)		Deficit			Interest			Equity

Balance, December 31, 2024		2,000,000	$	200		3,076,274	$	308		139	$	-	$	59,649,645			66,945	$	(397,969	)	$	-	$	(52,373,248	)	$	(2,137,789	)	$	4,741,147

Accretion of stock based compensation in connection with stock option grants		-		-		-		-		-		-		155,054			-		-			-		-			-			155,054

Issuance of common stock for cash, net of allocated offering costs of $568,000		-		-		1,200,000		120		-		-		4,531,880			-		-			-		-			-			4,532,000

Initial recording on noncontrolling interest		-		-		-		-		-		-		188,810			-		-			-		-			(188,810	)		-

Net loss for the period		-		-		-		-		-		-		-			-		-			-		(1,473,196	)		(145,914	)		(1,619,110	)

Balance, March 31, 2025		2,000,000		200		4,276,274		428		139		-		64,525,389			66,945		(397,969	)		-		(53,846,444	)		(2,472,513	)		7,809,091

Accretion of stock based compensation in connection with stock option grants		-		-		-		-		-		-		157,120			-		-			-		-			-			157,120

Accretion of stock based professional fees in connection with stock option grants		-		-		-		-		-		-		1,492			-		-			-		-			-			1,492

Changes in noncontrolling interest		-		-		-		-		-		-		(7,280	)		-		-			-		-			7,280			-

Net loss for the period		-		-		-		-		-		-		-			-		-			-		(1,216,872	)		(140,317	)		(1,357,189	)

Balance, June 30, 2025		2,000,000		200		4,276,274		428		139		-		64,676,721			66,945		(397,969	)		-		(55,063,316	)		(2,605,550	)		6,610,514

Common stock issued for services		-		-		55,000		5		-		-		111,645			-		-			-		-			-			111,650

Accretion of stock based compensation in connection with stock option grants		-		-		-		-		-		-		197,651			-		-			-		-			-			197,651

Accretion of stock based professional fees in connection with stock option grants		-		-		-		-		-		-		6,239			-		-			-		-			-			6,239

Changes in noncontrolling interest		-		-		-		-		-		-		7,280			-		-			-		-			(7,280	)		-

Net loss for the period		-		-		-		-		-		-		-			-		-			-		(1,201,477	)		(30,004	)		(1,231,481	)

Balance, September 30, 2025		2,000,000	$	200		4,331,274	$	433		139	$	-	$	64,999,536			66,945	$	(397,969	)	$	-	$	(56,264,793	)	$	(2,642,834	)	$	5,694,573

	Series B Preferred Stock				Common Stock				Common Stock to be Issued				Additional Paid-in		Treasury Stock					Accumulated Other Comprehensive		Accumulated			Noncontrolling		Total Stockholders’
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Shares		Amount			Gain (Loss)		Deficit			Interest		Equity

Balance, December 31, 2023		2,000,000	$	200		2,103,321	$	210		139	$	-	$	54,597,083		66,945	$	(397,969	)	$	34,553	$	(48,134,088	)	$	-	$	6,099,989

Accretion of stock-based compensation in connection with stock option grants		-		-		-		-		-		-		6,695		-		-			-		-			-		6,695

Accretion of stock-based professional fees in connection with stock option grants		-		-		-		-		-		-		22,019		-		-			-		-			-		22,019

Issuance of common shares in subsidiary for services		-		-		-		-		-		-		22,500		-		-			-		-			-		22,500

SEC Form 10-Q filed by Myseum Inc.